Find your next paid study

Englewood Hospital and Medical CenterNCT06681818

~$10 – $750

Actual pay is set by the research site.

Solid Tumor, AdultMetastatic Solid TumorRefractory Cancer+4 more

An Open-Label, Multicenter, Multi-arm Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1805 in Adults With Advanced Solid Tumors

This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monocl…

Actual pay is set by the research site.

Sairopa B.V.NCT05856981

Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeAstrocytoma, Grade III

A Phase 1/2 Open-label Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of zedoresertib combined with temozolomid…

Debiopharm International SANCT05765812

Actual pay is set by the research site.

Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0: Towards Expanding Our Understanding of Neonatal Acute Kidney Injury

There is a growing focus on short- and long-term kidney health in neonates, including those with acute kidney injury (AKI). AKI occurs commonly in the Neonatal…

Acute Kidney InjuryFluid OverloadPrematurity Complications+4 more

Indiana UniversityNCT06823115

~$10 – $750

Actual pay is set by the research site.

Metastatic Breast CancerMetastatic Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma+2 more

Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-label, Multicenter Trial of Oral Zongertinib (BI 1810631) Alone or in Combination With Other Agents for the Treatment of Patients With Advanced HER2+ Metastatic Breast Cancer (mBC), Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (mGEAC), or Metastatic Colorectal Cancer (mCRC)

This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take par…

Actual pay is set by the research site.

LiposarcomaProstate CancerAdvanced Breast Cancer+2 more

A PHASE 1/2A STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 adm…

Actual pay is set by the research site.

PfizerNCT04557449

Head and Neck CancerHead and Neck Small Cell CarcinomaMetastatic Head and Neck Cancer+1 more

Feasibility Trial of Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

This is a feasibility trial studying anti-PD-1 therapy (Pembrolizumab) among patients with R/M HNSCC, delivered with ultrasound-induced microbubble cavitation,…

Thomas Jefferson UniversityNCT07501650

~$150 – $3,000

Actual pay is set by the research site.

Phase 2

A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer

This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosi…

Hereditary Leiomyomatosis and Renal Cell CarcinomaPapillary Renal Cell CarcinomaRenal Cell Carcinoma+3 more

National Cancer Institute (NCI)NCT04981509

~$75 – $1,800

Actual pay is set by the research site.

Phase 2

A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage ac…

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRecurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)NCT03739814

~$75 – $1,800

Actual pay is set by the research site.

Solid TumorLocally Advanced Non-Small Cell Lung CancerMetastatic Non-Small Cell Lung Cancer

A Phase 1b/2, Multicenter, 2-part, Open-label Trial to Evaluate DS-3939a in Participants With Solid Tumors

The primary purpose of the study is to evaluate the safety, tolerability, and efficacy of DS-3939a in combination with other anticancer agents or as a monother…

Daiichi SankyoNCT07739966

Actual pay is set by the research site.

Phase 3

A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY

This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients wi…

Urothelial CancerUrinary Bladder Neoplasms

Astellas Pharma Global Development, Inc.NCT07566156

~$50 – $2,100

Actual pay is set by the research site.

Advanced or Metastatic Non-small Cell Lung Cancer

A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer

The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combinatio…